Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the peak of the season, a number they hope will increase as more women are ...

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that ...

2025年7月31日，珠海泰诺麦博制药股份有限公司（以下简称，泰诺麦博）递表上交所科创板，保荐机构为华泰联合。站在新的起点上，泰诺麦博作为科创板第五套上市标准重启后首家受理企业，备受市场关注。

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

While children with comorbid conditions were at higher risk of RSV-hospitalisation, the importance of socio-demographic risk ...

NYC Health said the Legionnaires' disease outbreak in Central Harlem is now up to 73 cases, including 3 deaths, an increase ...

当然，这款产品也面临已上市药物和在研药物的竞争。全球范围已上市竞品包括阿斯利康制药的帕利珠单抗、阿斯利康制药和赛诺菲制药联合开发的尼塞韦单抗、默沙东制药的Clesrovimab以及辉瑞的妊娠女性RSV疫苗Abrysvo（RSV-preF）。

格隆汇获悉，珠海泰诺麦博制药股份有限公司（简称“泰诺麦博”）于7月31日向上交所递交了招股书，拟采用第五套标准寻求科创板上市，由华泰联合证券担任保荐人。